Ideas
Buy memory semis on external pullbacks
Memory semiconductors are in a strong upcycle: Micron's rising target prices, capacity shifts from DRAM to HBM, and improving NAND demand suggest the memory shortage is real. Any 3-5% pullback in Samsung Electronics or SK hynix caused by external macro or news shocks should be treated as a buying opportunity.
Shipbuilding rally likely resumes in first half
Shipbuilding has regained upward momentum, led by Hanwha Ocean. Order momentum remains alive, and the sector is likely to stage another rally within the first half of the year.
Defense order momentum supports first-half rally
Defense stocks are re-accelerating on Trump's defense budget increase and rising geopolitical risk. Order momentum remains alive for Hanwha Aerospace, Hyundai Rotem, and Korea Aerospace Industries, so another rally is likely in the first half.
AI requires nuclear and SMR power
AI data centers need massive, stable, high-quality power that renewables, gas turbines, and batteries cannot reliably provide, making nuclear and especially SMRs essential. Uranium producers are already receiving government support, and Trump could ignite the sector by subsidizing nuclear/SMR operators such as NuScale and Oklo.
Doosan order backlog supports higher price
Doosan Enerbility's order backlog is long-cycle, 7 to 15 years, and can extend into the 2030s; gas turbines add shorter-cycle orders. Despite a high valuation, continued orders support the stock, with a likely break above 100,000 won and about 120,000 won if subsidy headlines emerge.
Hyundai E&C leveraged to 6.6GW project
Hyundai E&C is the construction beneficiary of a project plan to build 6.6GW of power by 2035. The story is simple: Doosan supplies turbines and Hyundai E&C handles construction, which drove the stock's sharp move.
Substrate sector rebound is worth watching
The semiconductor substrate/PCB sector has corrected and is now worth watching for a counterattack. Data-center substrate demand remains strong, and valuation has reset from extreme levels, though earnings guidance or price hikes are needed to confirm the rebound.
Isu Petasys pullback may be opportunity
Isu Petasys fell mainly because valuation had run too far, not because copper and gold costs suddenly became a new problem. It has de-rated from about 45x P/E to below 40x; if it falls into the low 100,000 won range, it may become an opportunity, especially with expansion talk indicating tight supply.
TLB preferred over Simmtech for data centers
TLB looks better than Simmtech. Simmtech has repeatedly disappointed investors and faces trust issues related to Simmtech Holdings, while TLB had a healthy time correction, is set to rise again, and has strong data-center substrate exposure even if small-cap exposure is not yet large.
TLB preferred over Simmtech for data centers
TLB looks better than Simmtech. Simmtech has repeatedly disappointed investors and faces trust issues related to Simmtech Holdings, while TLB had a healthy time correction, is set to rise again, and has strong data-center substrate exposure even if small-cap exposure is not yet large.
Hyosung, Hyundai Electric gain US grid demand
Power equipment makers should rise further, with US grid demand as the key driver. Korea's 765kV transformer expertise is being offered to US utilities, and Hyosung Heavy Industries and Hyundai Electric are the main beneficiaries as they expand US plants to meet strong demand.
Alteogen JPM catalysts outweigh UBS sell
Alteogen is a key JPMorgan Healthcare Conference name on the final day. Its SC platform is being incorporated into partner programs such as Daiichi Sankyo and Roche/ABL Bio, and timelines or news flow should emerge; the UBS sell rating looks overly harsh because foreign sell reports often overshoot.
D&D Pharmatech has JPM licensing catalysts
D&D Pharmatech is a hidden JPM healthcare conference idea. Pfizer's oral-link discussion, Sanofi's Dupixent SC formulation potential, and the company's MASH exposure make it a licensing and news-flow candidate that deserves attention.
HanAll restructuring is positive, not bad
HanAll Biopharma's decline on the Roivant-related restructuring was misread. Roivant acquired the subsidiary and license house and restructured the pipeline to prioritize near-term approvable assets for a better sale, which is actually positive for HanAll and warrants a re-rating.
Hanmi MASH drug deserves attention
MASH is becoming a major next-generation pharma keyword because the patient pool is large, especially in the US. Hanmi Pharm's efinopegdutide is a key MASH treatment candidate, and the name deserves attention with possible news flow.
This 815 Money Talk (815머니톡) video, published January 13, 2026,
features Lee Kwon-hee
discussing 005930.KS, 000660.KS, Korean shipbuilding sector, 042660.KS, 012450.KS, 064350.KS, 047810.KS, URA, SMR, OKLO, 034020.KS, 000720.KS, Semiconductor substrate/PCB sector, 007660.KS, TLB, 222800.KQ, 298040.KS, 267260.KS, 196170.KQ, 347850.KQ, 009420.KS, 128940.KS.
15 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Lee Kwon-hee
· Tickers:
005930.KS,
000660.KS,
Korean shipbuilding sector,
042660.KS,
012450.KS,
064350.KS,
047810.KS,
URA,
SMR,
OKLO,
034020.KS,
000720.KS,
Semiconductor substrate/PCB sector,
007660.KS,
TLB,
222800.KQ,
298040.KS,
267260.KS,
196170.KQ,
347850.KQ,
009420.KS,
128940.KS
